KPTI — Karyopharm Therapeutics Inc.

Karyopharm Therapeutics (KPTI) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $35.1 million, up from $30 million year-over-year.
• U.S. XPOVIO Net Product Revenue: $29.2 million, compared to $21.1 million in Q1 2025, driven by improved gross-to-net dynamics (21.8% vs. 45% in the prior year).
• R&D Expenses: $33.8 million; SG&A Expenses: $26.7 million, both consistent year-over-year.
• Net Loss: $22.4 million, slightly improved from $23.5 million in the previous year.
• Cash Position: Ended the quarter with $91.2 million, including $50 million raised in Q1, expected to fund operations into late Q3 2026.
• Full Year Guidance: Reaffirmed total revenue of $130 million to $150 million, with U.S. XPOVIO net product revenue expected between $115 million and $130 million.

2. Strategic Updates and Business Highlights

• Clinical Programs:
  • Reported positive top-line results from the Phase III SENTRY trial for myelofibrosis, showing significant spleen volume reduction and promising overall survival signals.
  • Completed enrollment in the Phase III EC042 trial for endometrial cancer, with top-line data expected in mid-2026.
• Commercial Strategy: Focus on leveraging existing relationships in community and academic settings to prepare for potential launches in myelofibrosis and endometrial cancer.
• Market Opportunity: Potential for selinexor in myelofibrosis to achieve up to $1 billion in U.S. peak annual revenue due to high unmet need and limited treatment options.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Engagement with the FDA regarding SENTRY results and preparation for ASCO presentation.
  • Anticipation of top-line results from EC042 in mid-2026, which could create significant value for the company.
• Operational Focus: Continued emphasis on financial discipline and managing spending while advancing key clinical and regulatory milestones.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Noted lower underlying demand for XPOVIO compared to Q1 2025 due to new market entrants, though the company has historically navigated such dynamics.
• Clinical Risks: Concerns about the deaths reported in the SENTRY trial, with ongoing evaluations needed to understand the implications fully.
• Market Dynamics: The company faces challenges in establishing selinexor as a standard treatment in a competitive landscape, particularly in myelofibrosis where JAK inhibitors dominate.

5. Notable Q&A Insights

• FDA Engagement: Plans to present a comprehensive data set to the FDA, including overall survival metrics and other analyses beyond initial top-line results.
• Compendia Inclusion: Discussion on the potential for selinexor to be included in treatment guidelines, with expectations that compelling data from ASCO will influence this process.
• Endometrial Cancer Trial: Clarification that the EC042 trial's patient population is well-powered to demonstrate meaningful benefits, despite a slight reduction in enrollment compared to initial targets.
• Safety Profile: Confidence in the safety profile of selinexor in the EC042 trial, with optimized dosing and supportive care measures expected to improve patient tolerability and adherence.

Overall, Karyopharm is positioned for potential growth through its clinical advancements and strategic commercial initiatives, while also facing challenges from competition and the need for regulatory approvals.